OOslo Read More It’s a case of history meets Hollywood2026-08-19 The eras of “The Odyssey” and the Vikings happened about 2,000 years apart — so how did a…
BBrussels Read More Holguín Meets von der Leyen and Fitto in Brussels2026-07-23 UN Secretary-General’s Personal Envoy on Cyprus María Ángela Holguín met European Commission President Ursula von der Leyen and…
NNovo Nordisk Read More Novo Nordisk’s Rally Meets a Revenue Reckoning: Buyback Momentum Clashes with 2026 Guidance2026-07-17 Novo Nordisk has staged a striking recovery over the past month, with the stock climbing 17% even as…
NNovo Nordisk Read More Novo Nordisk’s Rally Faces a Test: Medicare Tailwinds Meets Analyst Caution and a Billion-Dollar P2026-07-06 The past month has brought some much-needed relief to Novo Nordisk shareholders. After shedding nearly a third of…
NNovo Nordisk Read More Novo Nordisk’s Record Pill Launch Meets a Cybersecurity Reality Check2026-06-16 The Danish drugmaker is living two parallel stories this quarter. One is about the Wayovy pill smashing prescription…
NNovo Nordisk Read More Novo Nordisk’s Pill Breakthrough Meets a Cybersecurity Reality Check2026-06-13 The same week that brought Novo Nordisk a historic regulatory green light for its oral weight-loss pill also…
VVilnius Read More AB Akola Group presentation at Nasdaq Vilnius CEO Meets Investors webinar2026-06-04 On 4 June 2026, AB Akola Group participated in the virtual investor event “CEO Meets Investors”, organized by…
NNovo Nordisk Read More Novo Nordisk Bets on Buybacks and Pipeline Data as Prescription Boom Meets Washington Pricing Pressu2026-06-02 Novo Nordisk’s oral obesity therapy drives 2M prescriptions in 5 months, but shares tumble 48% from peak amid…
NNovo Nordisk Read More Novo Nordisk’s Summer of Reckoning: Prescription Dominance Meets Pipeline Verdict2026-06-02 Novo Nordisk’s oral Wegovy prescriptions outpace Eli Lilly’s Foundayo 2.4x, yet shares are down 45% from highs. Upcoming…
NNovo Nordisk Read More Novo Nordisk Enters a Pivotal Week: Pipeline Data Meets a Skeptical Market2026-05-31 Novo Nordisk shares slide 35% in 12 months as market awaits pivotal CagriSema Phase 3 results at ADA.…
NNovo Nordisk Read More Novo Nordisk’s Double Play: Digital Authority Meets Clinical Depth as Semaglutide’s Reach Widens2026-05-21 Wegovy tops AI searches; semaglutide shows 63% MASH resolution; oral pill gains momentum. Novo Nordisk faces mixed Q1…
NNovo Nordisk Read More Novo Nordisk’s Billion-Dollar Buyback Meets a Pricing Squeeze and Digital Dominance in Obesity Marke2026-05-21 Novo Nordisk repurchases billions in B-shares amid 44% stock drop, buoyed by strong Wegovy sales and a digital…